Patents Assigned to NUVATION BIO INC.
  • Anti-cancer nuclear hormone receptor-targeting compounds
    Patent number: 12208141
    Abstract: The disclosure relates to anti-cancer compounds derived from nuclear steroid receptor binders, to products containing the same, as well as to methods of their use and preparation.
    Type: Grant
    Filed: September 22, 2023
    Date of Patent: January 28, 2025
    Assignee: NUVATION BIO INC.
    Inventors: David Hung, Son Minh Pham, Sarvajit Chakravarty, Jiyun Chen, Jayakanth Kankanala, Jeremy D. Pettigrew, Anup Barde, Anjan Kumar Nayak
  • Anti-cancer nuclear hormone receptor-targeting compounds
    Patent number: 12006314
    Abstract: The disclosure relates to anti-cancer compounds derived from nuclear steroid receptor binders, such as a compound of Formula I: or a tautomer, stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog, or pharmaceutically acceptable salt thereof, to products containing the same, as well as to methods of their use and preparation.
    Type: Grant
    Filed: May 2, 2022
    Date of Patent: June 11, 2024
    Assignee: NUVATION BIO INC.
    Inventors: David Hung, Jayakanth Kankanala, Christopher Paul Miller, Jeremy David Pettigrew, Son Minh Pham, Ihab S. Darwish
  • Anti-cancer nuclear hormone receptor-targeting compounds
    Patent number: 11834458
    Abstract: The disclosure relates to anti-cancer compounds derived from nuclear steroid receptor binders, to products containing the same, as well as to methods of their use and preparation.
    Type: Grant
    Filed: March 22, 2022
    Date of Patent: December 5, 2023
    Assignee: NUVATION BIO INC.
    Inventors: David Hung, Jayakanth Kankanala, Christopher Paul Miller, Jeremy David Pettigrew, Son Minh Pham, Ihab S. Darwish
  • Anti-cancer nuclear hormone receptor-targeting compounds
    Patent number: 11826430
    Abstract: The disclosure relates to anti-cancer compounds derived from nuclear steroid receptor binders, to products containing the same, as well as to methods of their use and preparation.
    Type: Grant
    Filed: May 13, 2020
    Date of Patent: November 28, 2023
    Assignee: NUVATION BIO INC.
    Inventors: David Hung, Son Minh Pham, Sarvajit Chakravarty, Jiyun Chen, Jayakanth Kankanala, Jeremy D. Pettigrew, Anup Barde, Anjan Kumar Nayak
  • Heterocyclic compounds as BET inhibitors
    Patent number: 11584756
    Abstract: Novel bromodomain and extraterminal domain (BET) inhibitors and to therapeutic methods of treating conditions and diseases using these novel BET inhibitors are provided.
    Type: Grant
    Filed: July 1, 2020
    Date of Patent: February 21, 2023
    Assignee: NUVATION BIO INC.
    Inventors: Son Minh Pham, Sarvajit Chakravarty, Jayakanth Kankanala, Jiyun Chen, Chris P. Miller, Jeremy D. Pettigrew, Anjan Kumar Nayak, Anup Barde
  • Substituted pyrazolo[3,4-d]pyrimidines as Wee1 inhibitors
    Patent number: 11332473
    Abstract: This invention provides for substituted pyrazolo[3,4-d]pyrimidine compounds of the Formula (I): as Wee1 inhibitors. The substituted pyrazolo[3,4-d]pyrimidine compounds may find use as therapeutic agents for the treatment of diseases. The substituted pyrazolo[3,4-d]pyrimidine compounds may also find particular use in oncology.
    Type: Grant
    Filed: April 8, 2020
    Date of Patent: May 17, 2022
    Assignee: NUVATION BIO INC.
    Inventors: Sarvajit Chakravarty, Son Minh Pham, Jayakanth Kankanala, Brahmam Pujala, Sanjeev Soni, Puja Jaiswal, Deepak Palve, Varun Kumar
  • 1,8-naphthyridinone compounds and uses thereof
    Patent number: 11254670
    Abstract: 1,8-naphthyridinone compounds as modulators of an adenosine receptor are provided. The compounds may find use as therapeutic agents for the treatment of diseases mediated through a G-protein-coupled receptor signaling pathway and may find particular use in oncology.
    Type: Grant
    Filed: January 17, 2020
    Date of Patent: February 22, 2022
    Assignee: NUVATION BIO INC.
    Inventors: Son Minh Pham, Jayakanth Kankanala, Pradeep S. Jadhavar, Baban Mohan Mulik, Farha Khan, Sreekanth A. Ramachandran
  • Heterocyclic compounds as kinase inhibitors
    Patent number: 11174252
    Abstract: Heterocyclic compounds of Formula (J) as CDK4 or CDK6 or other CDK inhibitors are provided. The compounds may find use as therapeutic agents for the treatment of diseases and may find particular use in oncology.
    Type: Grant
    Filed: February 15, 2019
    Date of Patent: November 16, 2021
    Assignee: NUVATION BIO INC.
    Inventors: Son Minh Pham, Sarvajit Chakravarty, Jayakanth Kankanala, Brahmam Pujala, Amit Shete, Bhawana Bhatt, Anil Kumar Agarwal, Sanjeev Soni, Jiyun Chen
  • Heterocyclic compounds as adenosine antagonists
    Patent number: 11028058
    Abstract: Aminopyrazine compounds as modulators of an adenosine receptor are provided. The compounds may find use as therapeutic agents for the treatment of diseases mediated through a G-protein-coupled receptor signaling pathway and may find particular use in oncology.
    Type: Grant
    Filed: July 18, 2018
    Date of Patent: June 8, 2021
    Assignee: NUVATION BIO INC.
    Inventors: Son Minh Pham, Jiyun Chen, Amantullah Ansari, Pradeep S. Jadhavar, Varshavekumar S. Patil, Farha Khan, Sreekanth A. Ramachandran, Anil Kumar Agarwal, Sarvajit Chakravarty
  • Heterocyclic compounds and uses thereof
    Patent number: 10807994
    Abstract: Heterocyclic compounds of Formula (I): as Wee1 inhibitors are provided. The compounds may find use as therapeutic agents for the treatment of diseases and may find particular use in oncology.
    Type: Grant
    Filed: October 9, 2018
    Date of Patent: October 20, 2020
    Assignee: NUVATION BIO INC.
    Inventors: Sarvajit Chakravarty, Son Minh Pham, Jayakanth Kankanala, Anil Kumar Agarwal, Brahmam Pujala, Sanjeev Soni, Satish K. Arya, Deepak Palve, Varun Kumar
  • 1,8-naphthyridinone compounds and uses thereof
    Patent number: 10793561
    Abstract: 1,8-naphthyridinone compounds as modulators of an adenosine receptor are provided. The compounds may find use as therapeutic agents for the treatment of diseases mediated through a G-protein-coupled receptor signaling pathway and may find particular use in oncology.
    Type: Grant
    Filed: July 18, 2018
    Date of Patent: October 6, 2020
    Assignee: NUVATION BIO INC.
    Inventors: Son Minh Pham, Jiyun Chen, Amantullah Ansari, Pradeep S. Jadhavar, Varshavekumar S. Patil, Farha Khan, Sreekanth A. Ramachandran, Anil Kumar Agarwal, Sarvajit Chakravarty